Table 1.
Anti-HEV IgG prevalence, overall, and by age and gender (percentages and absolute numbers of positives)
| 2003 | 2006 | 2009 | 2012 | 2015 | |
|---|---|---|---|---|---|
| Overall | 32.8% (197/600) | 22.5% (135/600) | 22.3% (134/600) | 17.7% (106/600) | 17.8% (107/600) |
| Gender | |||||
| Female | 34.3% (103/300) | 18.7% (56/300) | 18.3% (55/300) | 16.7% (50/300) | 16.0% (48/300) |
| Male | 31.3% (94/300) | 26.3% (79/300) | 26.3% (79/300) | 18.7% (56/300) | 19.7% (59/300) |
| Age group | |||||
| 20–29 years | 23.0% (69/300) | 19.0% (57/300) | 17.0% (51/300) | 13.3% (40/300) | 15.7% (47/300) |
| 30–39 years | 42.7% (128/300) | 26.0% (78/300) | 27.7% (83/300) | 22.0% (66/300) | 20.0% (60/300) |